Form D · Pharmaceuticals
Mira1a Therapeutics, Inc.
Baltimore, MD · CIK 0001904286
Offering snapshot reported Aug 1, 2022 · SEC filing
- Reported sold
- $6.51M Offering amount: $6.51M
- Investors reported
- 76 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 9, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 1, 2022 | Initial | $6,511,000 | No comparison | 76 | SEC filing |
| Aug 1, 2022 | Initial | $625,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $292K
- Finders' fees
- $0
- Form D file number
- 021-454387
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Skyway Capital Markets | 124630 |
Source: Form D, filed Aug 1, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Chris Chapman, Md | Director |
| Adam Kaplin, Md, Ph D | Executive |
| Brad Kroenig | Director |
| Hugh Mc Coll Iii | Director |
| James Mc Nulty, Cpa | Executive |
| Paul Rivard, Esq | Executive |
| Josh Silverman | Director |
| Talhia Tuck, Jd | Director |
| Jude Uzonwanne | Executive |
| Dave Vorhoff | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
855 N Wolfe Street #601
Baltimore, MD, 21205
Baltimore, MD, 21205